← Back to Search

Unknown

CHK336 for Healthy Subjects

Phase 1
Waitlist Available
Research Sponsored by Chinook Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Body mass index (BMI) between 19 and 32 kg/m2, inclusive, (between 30.0 and < 40.0 kg/m2 for SAD Cohort A8) at screening.
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 28 days
Awards & highlights

Study Summary

This trial is testing a new drug to see if it's safe and effective.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
Your body mass index (BMI) falls between 19 and 32 kg/m2 (or between 30.0 and less than 40.0 kg/m2 for a specific group).

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 28 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 28 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
To evaluate the safety and tolerability of single ascending doses and multiple ascending doses of CHK-336 in HV
Secondary outcome measures
Pharmacokinetic measure of AUC (0-∞)
Pharmacokinetic measure of AUC for up to 24 hours (AUC0-24)
Pharmacokinetic measure of AUC for up to last measurable time point (AUC0-T)
+6 more

Trial Design

4Treatment groups
Experimental Treatment
Group I: Part B: Healthy Volunteers: Multiple Ascending dosesExperimental Treatment2 Interventions
5 dose groups with doses ranging from 30mg to 500mg. Given daily for 14 days, under fasting condition.
Group II: Part A: Otherwise Healthy volunteer with Class I or Class II obesity, Single Ascending doseExperimental Treatment2 Interventions
125mg, under fasting condition.
Group III: Part A: Healthy Volunteers: Single ascending dosesExperimental Treatment2 Interventions
Six dose groups ranging from 15mg to 500mg, under fasting condition.
Group IV: Part A: Healthy Volunteer: Single Ascending dose under fed conditionExperimental Treatment1 Intervention
60mg under fed condition.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Placebo
1995
Completed Phase 3
~2670

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Chinook Therapeutics, Inc.Lead Sponsor
7 Previous Clinical Trials
540 Total Patients Enrolled
Charlotte Jones-Burton, MD, MSStudy DirectorChinook Therapeutics
2 Previous Clinical Trials
432 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has CHK336 achieved official governmental authorization for use?

"Our team at Power has assessed CHK336 as a 1 on the safety scale due to its Phase 1 status. This indicates that there is restricted data available in regards to both efficacy and security."

Answered by AI

What is the current enrollment size of this experiment?

"Affirmative. Clinicaltrials.gov data indicates that enrolment for this clinical trial is ongoing; it was initially posted on April 8th 2022 and the latest update came on July 18th 2022. There are 104 slots to be filled at a single medical site."

Answered by AI

Is there still an opportunity for volunteers to join this research project?

"According to the clinicaltrials.gov listing, this medical research is currently recruiting potential participants. This trial was first published on April 8th 2022 and has seen its latest edit a mere two months ago, on July 18th of the same year."

Answered by AI

Who is eligible to participate in this investigation?

"This medical study is seeking 104 participants between the ages of 18-45 who are in good physical health. Candidates must meet certain criteria including having a Body Mass Index (BMI) range from 19 to 32 kg/m2, agreeing to use contraception accordingly, and providing negative urine drug, tobacco, and breath alcohol tests at screening and Day-3. Furthermore all eligible individuals must be able to provide informed consent and comply with overnight stays for clinical visits during the duration of this trial."

Answered by AI

Is the study open to geriatric patients?

"According to the enrollment criteria, candidates for this study must be between 18 and 45 years of age."

Answered by AI
~30 spots leftby Mar 2025